Posted by Michael Wonder on 15 Oct 2022
Takeda receives positive CHMP opinion recommending approval of Dengue vaccine candidate in EU and Dengue endemic countries
14 October 2022 - TAK-003 recommended for the prevention of Dengue disease caused by any Dengue virus serotype in individuals four years of age and older in the EU and in Dengue endemic countries participating in the EU-M4all procedure.
Takeda today announced that the CHMP of the EMA recommended the approval of Takeda’s dengue vaccine candidate, TAK-003, for the prevention of dengue disease caused by any serotype in individuals four years of age and older in Europe and in dengue-endemic countries participating in the parallel EU-M4all procedure.
